Core Insights - Dingdang Health (09886) reported a revenue of RMB 2.327 billion for the six months ending June 30, 2025, representing a year-on-year increase of 2.6% [1] - The company recorded a loss attributable to owners of RMB 51.671 million, a reduction of 38.84% compared to the previous year [1] - Basic loss per share was RMB 0.04 [1] Revenue Growth - The increase in total revenue is attributed to the company's optimization of urban layout, focusing on key regions, and establishing cities like Beijing, Shanghai, and Shenzhen as "the best health service entry points for residents" [1] - The company actively expanded and densified its local smart pharmacy network, contributing to business growth [1] Operational Efficiency - The company improved its supply chain service levels in the layout of drugs and goods, leading to a significant enhancement in overall operational efficiency [1] - The narrowing of losses and improvement in performance were supported by an increase in gross margin to 35.0%, up by 1.9 percentage points year-on-year [1] - The effectiveness of refined operations and continuous cost reduction efforts resulted in a notable improvement in profitability [1]
叮当健康发布中期业绩，股东应占亏损5167.1万元，同比减少38.84%